Everolimus demonstrated strong potential as an effective tool for overcoming endocrine resistance in postmenopausal women with ER-positive, HER2-negative metastatic breast cancer resistant to AI therapy.
More From BioPortfolio on "Everolimus Shows Efficacy in Combating Endocrine Resistance in Breast Cancer"